mRNA vaccine effectiveness against hospitalisation due to severe acute respiratory infection (SARI) COVID-19 during Omicron variant predominance estimated from real-world surveillance data, Slovenia, February to March 2022

Euro Surveill. 2022 May;27(20). doi: 10.2807/1560-7917.ES.2022.27.20.2200350.ABSTRACTFor the period of predominance of SARS-CoV-2 Omicron variant in Slovenia, February to March 2022, we estimated mRNA vaccine effectiveness (VE) against severe acute respiratory infection (SARI) COVID-19 using surveillance data. In the most vulnerable age group comprising individuals aged 65 years and more, VE against SARI COVID-19 was 95% (95% CI: 95-96%) for those vaccinated with three doses, in comparison to 82% (95% CI: 79-84%) for those vaccinated with two doses. Such levels of protection were maintained for at least 6 months.PMID:35593166 | DOI:10.2807/1560-7917.ES.2022.27.20.2200350

Source: Euro Surveill - May 20, 2022 Category: Infectious Diseases Authors: Marta Grgi č Vitek Irena Klavs Veronika U čakar Marjana Vrh Maja Mrzel Mojca Serdt Mario Fafangel Source Type: research